• PONTEVIA is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1
• The onset of efficacy of galcanezumab is within 1 week in a majority of patients.2
• Galcanezumab 120mg given once monthly was efficacious and well tolerated.3
1. Pontevia Malaysia Approved Prescribing Information, Version 06 Nov 2020.
2. Goadsby PJ, et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 2019;90:939–944.
3. Skljarevski V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.
Adverse events should be reported to firstname.lastname@example.org.
For healthcare professionals only
Product Highlight - Pontevia
16 Mar 2022